BREAKING THE SPELL OF “DISEASE MANAGEMENT”
Once Mr. Gerrans pivoted his focus to curative technologies – including inventive concepts aimed at conditions like Lung Cancer, Asthma, Mesothelioma, and High Blood Pressure - doors that once opened started slamming shut. Investors who had once backed him stopped taking calls. Quietly, they told him why: he was disrupting the entrenched business paradigm they termed “Disease Management”. Dress it up as they wish, but their profit engine is reliant upon recurring revenue – in the form of pills, injections, and potions – not cures. Disease Management pacifies patients’ symptoms over their lifetime. It cures no one.
Think of High Blood Pressure, Diabetes and Asthma. These are common medical conditions which have addicted patients to daily regimens of renal denervation, insulin and bronchial dilator medications over their lifetimes. Conditions Mr. Gerrans has developed inventive concepts to cure.
Nonetheless, Dark Pharma has romanticized Disease Management as a constructive, multi-disciplinary collaboration for the good of Patient Care. The ruse is best evidenced in Wikipedia, as follows:
"Disease Management refers to a coordinated approach to improving the health outcomes of individuals with chronic conditions through structured programs and proactive care."
"What is Disease Management?
In Wikipedia's definition, please note the requirement of "medication adherence" and the general understanding that these 'chronic' conditions require "regular monitoring" over time. This definition creates the economic parameters and conditions which justify doctor office visits (for which Doctors receive up to $150 in payment just for the visit) and the pacification of symptoms via the consumption of medications, in perpetuity. This is not a definition justifying health. This is a definition justifying the business of healthcare.
Mr. Gerrans rejected this paradigm and this future for healthcare.
He chose cures.
COLLIDING WITH BIG MONEY’S GATEKEEPERS
Leaving the Fortune 500, Mr. Gerrans needed growth capital to bring curative tech to patients. What he encountered was an ecosystem where large financial actors and corporate incumbents effectively decide who wins and who loses – and cures, by definition, threaten recurring revenue. The message was blunt: play by our rules, or don’t play at all.
So, he changed the Rules.
LEGISLATING INNOVATION CAPITAL: INVENTING SOCIAL FINANCE & EQUITY CROWD FUNDING
Facing investment resistance and certain failure, Mr. Gerrans drew on his own self-directed IRA investing and the interest of friends and family who had witnessed his achievements up close. He initiated advocacy with congress to expand securities laws and regulations to incentivize capital gains tax credits for small business investment and to legalize social finance and crowd funding.
Mr. Gerrans architected and advocated legislative modification to the safe-harbor exemptions within SEC Regulation 'D', Rule 506(b) of the 1933 Securities Act to legalize the advertisement and promotion of Private Equity Investment Offerings to verified, accredited investors to open private markets to Main Street. The advocacy succeeded in creating a new Rule 506(c) under the 2012 JOBS Act. Using these rules, Mr. Gerrans raised over $70 Million for his Companies.
THE INCIDENTAL DISRUPTION OF ENTRENCHED COMPETITIVE INTERESTS IN THE WALL STREET ECOSYSTEM
Mr. Gerrans did not bow to Wall Street syndicates. The model of Social Finance and Equity Crowd Funding Mr. Gerrans innovated deployed new technological advances occurring in the early 2000's in Silicon Valley in cloud storage, electronic security, digital tracking and archiving, digital signatures, IRA investing, and Wire Funds Transfers - to automate, track, trace, validate and verify due diligence, automate banking, and expand access to capital.
In building a system and method of transparent data rooms, digital diligence, e-signatures, traceable funds movement, and IRA participation Mr. Gerrans reformed the legacy institutions on Wall Street in Investment Brokerage, Printing and Clearance Housing ('Book Running'), Securities Risk and Compliance Management, Private Equity and Venture Capital, and have irreversibly transformed the Wall Street and Main Street Securities eco-system, for the better. That stack has not just financed Sanovas; it modernized private capital formation and has served to enrich ordinary retirement portfolios that had long been fenced out.
SIGNIFICANCE
Mr. Gerrans ingenuity and resourcefulness have expanded access to research monies for Lung Cancer and have helped prolong and save the lives for thousands of individuals who are obtaining early Lung Screenings (See Lobbyist). Mr. Gerrans pioneering efforts in Social Finance have succeeded in bringing Wall Street resources and opportunities to Main Street Americans by helping thousands of Start-up Businesses and private individuals obtain investment Capital, Mortgages and Loans; and, by mobilizing Self-Directed IRA Investing to enable Americans to Retire with their financial security and dignity intact. For details, please read UC Berkeley's Case Study in 'Social Finance'.
EFFECT
As the adage goes: No Good Deed goes unpunished. Mr. Gerrans, his Company, his Family, his Employees and his Investors and the millions of patients who are being denied his innovative procedures and technologies have all been rendered casualties to Big Money, Dark Pharma and the Administrative Deep States protections of their "Disease Management" Eco-System. See 'Dark Pharma' for details.